Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies
Pharmacology, Toxicology and Pharmaceutical Science
1
6%
Biochemistry, Genetics and Molecular Biology
1
6%
Nursing and Health Professions
1
6%
Immunology and Microbiology
1
6%
Other
2
12%
Unknown
9
53%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2022.
All research outputs
#26,642,357
of 32,178,296 outputs
Outputs from Journal of Pancreatic Cancer
#38
of 53 outputs
Outputs of similar age
#348,141
of 454,957 outputs
Outputs of similar age from Journal of Pancreatic Cancer
#2
of 4 outputs
Altmetric has tracked 32,178,296 research outputs across all sources so far. This one is in the 9th percentile – i.e., 9% of other outputs scored the same or lower than it.
So far Altmetric has tracked 53 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 454,957 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.
